On Ngoc H, Kiptoo Paul, Siahaan Teruna J, Miller Donald W
Department of Pharmacology and Therapeutics, University of Manitoba , Winnipeg, Manitoba, Canada.
Mol Pharm. 2014 Mar 3;11(3):974-81. doi: 10.1021/mp400624v. Epub 2014 Feb 19.
The present work characterizes the effects of synthetic E-cadherin peptide (HAV) on blood-brain barrier (BBB) integrity using various techniques including magnetic resonance imaging (MRI) and near-infrared fluorescent imaging (NIRF). The permeability of small molecular weight permeability marker gadolinium diethylenetriaminepentaacetate (Gd-DTPA) contrast agent, the large molecular weight permeability marker, IRDye 800CW PEG, and the P-glycoprotein (P-gp) efflux transporter contrast agent, rhodamine 800 (R800), were examined in the presence and absence of HAV peptide. The results consistently demonstrated that systemic iv administration of HAV peptide resulted in a reversible disruption of BBB integrity and enhanced the accumulation of all the dyes examined. The magnitude of increase ranged from 2-fold to 5-fold depending on the size and the properties of the permeability markers. The time frame for BBB disruption with HAV peptide was rapid, occurring within 3-6 min following injection of the peptide. Furthermore, modulation of BBB permeability was reversible with the barrier integrity being restored within 60 min of the injection. The increased BBB permeability observed following HAV peptide administration was not attributable to changes in cerebral blood flow. These studies support the potential use of cadherin peptides to rapidly and reversibly modulate BBB permeability of a variety of therapeutic agents.
本研究利用包括磁共振成像(MRI)和近红外荧光成像(NIRF)在内的多种技术,对合成的E-钙黏蛋白肽(HAV)对血脑屏障(BBB)完整性的影响进行了表征。在存在和不存在HAV肽的情况下,检测了小分子通透性标记物钆二乙烯三胺五乙酸(Gd-DTPA)造影剂、大分子通透性标记物IRDye 800CW PEG以及P-糖蛋白(P-gp)外排转运体造影剂罗丹明800(R800)的通透性。结果一致表明,全身静脉注射HAV肽会导致血脑屏障完整性的可逆性破坏,并增强所有检测染料的蓄积。根据通透性标记物的大小和性质,增加幅度在2倍至5倍之间。HAV肽破坏血脑屏障的时间框架很快,在注射肽后3-6分钟内发生。此外,血脑屏障通透性的调节是可逆的,屏障完整性在注射后60分钟内恢复。HAV肽给药后观察到的血脑屏障通透性增加并非归因于脑血流量的变化。这些研究支持了钙黏蛋白肽在快速、可逆地调节多种治疗药物血脑屏障通透性方面的潜在应用。